Natco Pharma has received final approval for its 1st supplemental Abbreviated New Drug Application (sANDA) product from the US Food and Drug Administration (US FDA) filed from its new drug formulations facility in Vizag, Andhra Pradesh.
The sANDA, submitted as 'Prior Approval Supplement,' provides for company’s Vizag facility as an alternate site for manufacture of the approved drug product for the US market.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
